Provided by Tiger Fintech (Singapore) Pte. Ltd.

ENDRA Life Sciences Inc

7.17
-0.0600-0.83%
Volume:44.89K
Turnover:320.96K
Market Cap:5.40M
PE:-0.13
High:7.35
Open:7.23
Low:7.01
Close:7.23
Loading ...

ENDRA Life Sciences Inc - Expects No Revenue for Q2 2025 - SEC Filing

THOMSON REUTERS
·
10 Jul

ENDRA Life Sciences Reports No Revenue for Q2 2025, Narrows Net Loss to $1.3 Million

Reuters
·
10 Jul

ENDRA Life Sciences Files Preliminary Prospectus for Share, Warrant Offering

MT Newswires Live
·
09 Jul

ENDRA Life Sciences : Files for Offering of 15.7 Mln Shares of Common Stock- SEC Filing

THOMSON REUTERS
·
09 Jul

Top Premarket Gainers

MT Newswires Live
·
08 Jul

ENDRA Life Sciences Unveils Multisite Clinical Study to Enhance TAEUS Liver Device Accuracy Ahead of FDA Pivotal Trial

Reuters
·
16 Jun

ENDRA Life Sciences Inc. Faces Nasdaq Non-Compliance Over Stockholders' Equity, Given 45 Days to Submit Remedial Plan

Reuters
·
30 May

ENDRA Life Sciences Is Maintained at Buy by Ascendiant Capital

Dow Jones
·
30 May

ENDRA Life Sciences Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
16 May

BRIEF-ENDRA Life Sciences Provides A Business Update And Reports First Quarter 2025 Financial Results

Reuters
·
16 May

ENDRA Life Sciences Q1 EPS $(1.86) Beats $(4.08) Estimate

Benzinga
·
16 May

ENDRA Life Sciences Reports Q1 2025 Net Loss of $1.0M, Down from $2.8M in Q1 2024, as Cost-Cutting Measures Improve Financial Efficiency

Reuters
·
16 May

Press Release: ENDRA Life Sciences Provides a Business Update and Reports First Quarter 2025 Financial Results

Dow Jones
·
16 May

ENDRA Life Sciences Inc expected to post a loss of $4.08 a share - Earnings Preview

Reuters
·
09 May

Why Vertiv Holdings Shares Are Trading Higher By 17%; Here Are 20 Stocks Moving Premarket

Benzinga
·
23 Apr

ENDRA Life Sciences Is Maintained at Buy by Ascendiant Capital

Dow Jones
·
21 Apr

U.S. RESEARCH ROUNDUP-Lowe's, Netflix, Vulcan Materials

Reuters
·
21 Apr

ENDRA Life Sciences Inc : Ascendiant Capital Markets Cuts Target Price to $50 From $75

THOMSON REUTERS
·
21 Apr

Top broker says Mesoblast shares can rocket 100%

MotleyFool
·
08 Apr

ENDRA Life Sciences FY 2024 GAAP EPS $(56.94) Misses $(47.46) Estimate

Benzinga
·
31 Mar